Loading
InhaTarget Therapeutics turns the chemotherapy drug cisplatin into a dry powder that people breathe in, so more of it reaches lung tumours and less reaches the rest of the body. It has been tested alongside standard immunotherapy in advanced non-small cell lung cancer.
InhaTarget Therapeutics, a spin-off of the Universite libre de Bruxelles (ULB) established in August 2019 according to the company, is headquartered in Gosselies, Belgium, with an office on the ULB Plaine campus in Brussels. Its lead product CIS-DPI is a cisplatin dry powder for inhalation, given five times a week, largely at home, on top of standard immunotherapy with or without intravenous chemotherapy. The first-in-human phase 1/2a study CIS-DPI-01 in stage IV non-small cell lung cancer in Belgium, France and Spain (NCT06896890) was terminated and analysed, and the company reports encouraging preliminary signals; a redesigned study, CIS-DPI-11, was being prepared for regulatory submission in Belgium and France with approval expected by the end of 2026. The company also has an inhalable lipid nanoparticle platform for delivering immunomodulators and nucleic acids to lung macrophages, with partnered programmes including a STING-LNP for lung cancer. Founded in 2019, according to the company. Its first registered cancer trial, NCT06896890, was posted on ClinicalTrials.gov in March 2025.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/